Biogen Stock Explodes Higher After Alzheimer’s Drug Succeeds In Final-Phase Test
Biogen stock exploded higher Wednesday — bringing shares of other Alzheimer’s plays with it — after its experimental treatment succeeded in a final-phase test. X The results are sorely needed for Biogen (BIIB), which has long struggled to target the neurological disease. In the Phase 3 study, the drug called lecanemab removed built-up plaque in … Read more